Cerus ROE 2006-2018 | CERS

Current and historical return on equity (ROE) values for Cerus (CERS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Cerus ROE for the three months ending December 31, 2018 was -65.35%.
Cerus ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-12-31 $-0.06B $0.09B -64.59%
2018-09-30 $-0.05B $0.09B -67.75%
2018-06-30 $-0.05B $0.09B -80.95%
2018-03-31 $-0.06B $0.09B -109.45%
2017-12-31 $-0.06B $0.04B -153.85%
2017-09-30 $-0.06B $0.04B -144.00%
2017-06-30 $-0.06B $0.04B -121.90%
2017-03-31 $-0.07B $0.04B -105.69%
2016-12-31 $-0.06B $0.06B -87.20%
2016-09-30 $-0.06B $0.07B -78.53%
2016-06-30 $-0.07B $0.08B -75.43%
2016-03-31 $-0.06B $0.08B -66.32%
2015-12-31 $-0.06B $0.10B -54.37%
2015-09-30 $-0.06B $0.10B -67.97%
2015-06-30 $-0.06B $0.11B -72.26%
2015-03-31 $-0.05B $0.11B -79.01%
2014-12-31 $-0.04B $0.04B -87.64%
2014-09-30 $-0.03B $0.05B -55.87%
2014-06-30 $-0.04B $0.04B -83.33%
2014-03-31 $-0.03B $0.05B -75.98%
2013-12-31 $-0.04B $0.04B -90.26%
2013-09-30 $-0.04B $0.04B -93.57%
2013-06-30 $-0.02B $0.06B -57.89%
2013-03-31 $-0.02B $0.06B -58.62%
2012-12-31 $-0.02B $0.02B -86.49%
2012-09-30 $-0.02B $0.02B -120.55%
2012-06-30 $-0.02B $0.02B -94.44%
2012-03-31 $-0.02B $0.02B -127.27%
2011-12-31 $-0.02B $0.02B -103.03%
2011-09-30 $-0.01B $0.02B -61.11%
2011-06-30 $-0.02B $0.01B -100.00%
2011-03-31 $-0.02B $0.02B -101.49%
2010-12-31 $-0.02B $0.02B -104.62%
2010-09-30 $-0.02B $0.01B -129.03%
2010-06-30 $-0.02B $0.01B -115.79%
2010-03-31 $-0.02B $0.02B -102.33%
2009-12-31 $-0.02B $0.02B -100.00%
2009-09-30 $-0.03B $0.03B -95.41%
2009-06-30 $-0.03B $0.02B -91.06%
2009-03-31 $-0.03B $0.03B -83.22%
2008-12-31 $-0.03B $0.03B -67.42%
2008-09-30 $-0.03B $0.04B -66.67%
2008-06-30 $-0.04B $0.05B -60.09%
2008-03-31 $-0.04B $0.06B -66.92%
2007-12-31 $-0.05B $0.06B -59.60%
2007-09-30 $-0.03B $0.07B -36.15%
2007-06-30 $-0.02B $0.08B -27.67%
2007-03-31 $-0.01B $0.10B -12.83%
2006-12-31 $-0.01B $0.10B -6.13%
2006-09-30 $-0.01B $0.07B -18.46%
2006-06-30 $-0.01B $0.07B -21.24%
2006-03-31 $-0.01B $0.08B -20.83%
2005-12-31 $0.01B $0.04B 30.57%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.787B $0.061B
Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $129.838B 25.32
Medtronic (MDT) Ireland $112.952B 16.51
Stryker (SYK) United States $67.256B 24.66
Boston Scientific (BSX) United States $48.820B 23.72
Baxter (BAX) United States $37.991B 24.37
Zimmer Biomet Holdings (ZBH) United States $24.550B 15.71
Smith & Nephew SNATS (SNN) United Kingdom $16.615B 0.00
Canopy Growth (CGC) Canada $14.912B 0.00
ResMed (RMD) United States $14.218B 26.96
Aurora Cannabis (ACB) Canada $9.118B 64.29
Bio-Rad Laboratories (BIO) United States $8.765B 50.28
Perrigo (PRGO) Ireland $6.633B 10.75
Hill-Rom Holdings (HRC) United States $6.374B 19.72
Insulet (PODD) United States $4.900B 1642.60
GW Pharmaceuticals (GWPH) United Kingdom $4.701B 0.00
ICU Medical (ICUI) United States $4.568B 28.29
Haemonetics (HAE) United States $4.189B 37.16
Hutchison China MediTech (HCM) China $4.046B 0.00
Agios Pharmaceuticals (AGIO) United States $3.268B 0.00
Neogen (NEOG) United States $2.958B 48.10
NuVasive (NUVA) United States $2.784B 24.18
Quidel (QDEL) United States $2.365B 21.17
National Vision Holdings (EYE) United States $2.220B 43.66
Aphria (APHA) $1.917B 0.00
Phibro Animal Health (PAHC) United States $1.349B 19.38
VAREX IMAGING (VREX) United States $1.222B 23.93
Cardiovascular Systems (CSII) United States $1.190B 854.00
AtriCure (ATRC) United States $1.049B 0.00
Lantheus Holdings (LNTH) United States $0.931B 25.16
Omeros (OMER) United States $0.908B 0.00
PetIQ (PETQ) United States $0.862B 24.67
MacroGenics (MGNX) United States $0.791B 0.00
NanoString Technologies (NSTG) United States $0.737B 0.00
TG Therapeutics (TGTX) United States $0.689B 0.00
Evolus (EOLS) United States $0.681B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.666B 22.66
OraSure Technologies (OSUR) United States $0.594B 25.86
Surmodics (SRDX) United States $0.546B 79.43
LeMaitre Vascular (LMAT) United States $0.536B 25.46
Meridian Bioscience (VIVO) United States $0.531B 15.82
Quanterix (QTRX) United States $0.492B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.322B 0.00
Utah Medical Products (UTMD) United States $0.321B 20.88
Insys Therapeutics (INSY) United States $0.313B 0.00
BioLife Solutions (BLFS) United States $0.305B 125.85
Vapotherm (VAPO) United States $0.296B 0.00
Rockwell Medical (RMTI) United States $0.271B 0.00
Cytosorbents (CTSO) United States $0.219B 0.00
Owens & Minor (OMI) United States $0.213B 2.91
Zynex (ZYXI) United States $0.171B 18.31
Chimerix (CMRX) United States $0.133B 0.00
Bovie Medical (APYX) United States $0.131B 0.00
Fonar (FONR) United States $0.125B 6.68
Chembio Diagnostics (CEMI) United States $0.121B 0.00
Surface Oncology (SURF) United States $0.113B 0.00
Female Health (VERU) United States $0.088B 0.00
United-Guardian (UG) United States $0.088B 20.06
CAS Medical Systems (CASM) United States $0.072B 0.00
Neurotrope (NTRP) United States $0.071B 0.00
Trinity Biotech (TRIB) Ireland $0.071B 21.00
Oramed Pharmaceuticals (ORMP) United States $0.070B 0.00
ImmuCell (ICCC) United States $0.043B 0.00
Senestech (SNES) United States $0.034B 0.00
Valeritas Holdings (VLRX) United States $0.031B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.025B 0.00
Capricor Therapeutics (CAPR) United States $0.018B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
Akers Biosciences Inc (AKER) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.008B 13.71